YKYY017: meta-analysis of COVID-19 studies

All studies Serious outcomes Recovery Viral clearance RCTs Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−150%

Viral clearance (1)13%

RCTs (1)−150%

Early (1)−150%

00.511.5+

← YKYY017
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

YKYY017 COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Wang (DB RCT)−150%2.50 · 0.10–60.77progression1/1590/80

Early treatment−150%2.50 · 0.10–60.771/1590/80150% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.58

All studies−150%2.50 · 0.10–60.771/1590/80150% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5800.511.52+

Rotate screen for more detailsIncrease width for more details

← YKYY017
reduces riskYKYY017
increases risk →

c19early.org

October 2026

YKYY017 COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Wang (DB RCT)−150%2.50 · 0.10–60.77progression1/1590/80

Early treatment−150%2.50 · 0.10–60.771/1590/80150% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.58

All studies−150%2.50 · 0.10–60.771/1590/80150% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5800.511.52+

Rotate screen for more detailsIncrease width for more details

← YKYY017
reduces riskYKYY017
increases risk →

c19early.org

October 2026

YKYY017 COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Wang (DB RCT)31%0.69 · 0.54–0.88no recov.70 (n)69 (n)

Early treatment31%0.69 · 0.54–0.8870 (n)69 (n)31% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.0034

All studies31%0.69 · 0.54–0.8870 (n)69 (n)31% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.003400.511.52+

Rotate screen for more detailsIncrease width for more details

← YKYY017
reduces riskYKYY017
increases risk →

c19early.org

October 2026

YKYY017 COVID-19 viral clearance results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Wang (DB RCT)13%0.87 · 0.75–1.02viral load70 (n)69 (n)

Early treatment13%0.87 · 0.75–1.0270 (n)69 (n)13% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.079

All studies13%0.87 · 0.75–1.0270 (n)69 (n)13% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.07900.511.52+

Rotate screen for more detailsIncrease width for more details

← YKYY017
reduces riskYKYY017
increases risk →

c19early.org

October 2026

YKYY017 COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Wang (DB RCT)−150%2.50 · 0.10–60.77progression1/1590/80

Early treatment−150%2.50 · 0.10–60.771/1590/80150% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.58

All studies−150%2.50 · 0.10–60.771/1590/80150% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5800.511.52+

Rotate screen for more detailsIncrease width for more details

← YKYY017
reduces riskYKYY017
increases risk →

c19early.org

October 2026

YKYY017 COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Wang (DB RCT)−150%2.50 · 0.10–60.77progression1/1590/80

Early treatment−150%2.50 · 0.10–60.771/1590/80150% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.58

All studies−150%2.50 · 0.10–60.771/1590/80150% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5800.511.52+

Rotate screen for more detailsIncrease width for more details

← YKYY017
reduces riskYKYY017
increases risk →

c19early.org

October 2026

YKYY017 COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Wang (DB RCT)−150%2.50 · 0.10–60.77progression1/1590/80 Wang (DB RCT)31%0.69 · 0.54–0.88no recov.70 (n)69 (n) Wang (DB RCT)36%0.64 · 0.45–0.92no recov.65 (n)69 (n) Wang (DB RCT)27%0.73 · 0.52–1.04no recov.70 (n)69 (n) Wang (DB RCT)13%0.87 · 0.75–1.02viral load70 (n)69 (n) Wang (DB RCT)16%0.84 · 0.67–1.05viral load65 (n)69 (n) Wang (DB RCT)10%0.90 · 0.74–1.11viral load70 (n)69 (n)

00.511.52+

Rotate screen for more detailsIncrease width for more details

← YKYY017
reduces riskYKYY017
increases risk →